The FDA on 3 February gave its approval to Pfizer to market Ibrance (palbociclib) as a treatment for metastatic breast cancer (MBC) – granting the nod more than two months ahead of schedule.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?